Overview
Weight loss medication news rarely makes the morning shows, but this week's did. On November 16, 2026, results from the STEP YOUNG trial were published in the New England Journal of Medicine and presented at ObesityWeek 2026: weekly semaglutide — the same medication sold as Wegovy — cut BMI by an average of 13.5% in children ages 6 to 11 with obesity, while children on placebo saw their BMI rise 2.7%. Wegovy is currently FDA-approved only for ages 12 and up, and Novo Nordisk has said it plans to ask the FDA to lower that age. For parents weighing what this means for their kids — and for adults managing their own weight at the same time — here's what the data actually shows, what doctors are cautioning, and how to think about it.

